PO-SCORAD与SCORAD在幼儿中的可解释性与临床实用性新数据
研究基于335名2-6岁以轻中度特应性皮炎为主的儿童、为期12周的随机对照试验数据,评估SCORAD、PO-SCORAD、POEM与IGA的相关性及可解释性。结果显示PO-SCORAD与SCORAD强相关(r=0.874),8周内PO-SCORAD曲线下面积显著大于SCORAD(p=0.0002),且发作前7天PO-SCORAD评分显著升高。结论认为PO-SCORAD稳健可靠,每周使用两次可能改善AD患者管理。
要点
- PO-SCORAD与SCORAD强相关(r=0.874),与POEM(r=0.734)和IGA(r=0.613)也相关。
- SCORAD分类与IGA类别最佳匹配(k=0.68)的界值为:<12、12-25、≥25。
- 8周内PO-SCORAD曲线下面积显著大于SCORAD(p=0.0002),能更好估计就诊间期疾病严重度。
核心结论
- PO-SCORAD稳健可靠,在常规临床实践中可能比其它评分具有更大实用性。
- 每周使用两次PO-SCORAD可能改善特应性皮炎患者的管理。
研究设计与样本
- 数据来自一项12周随机对照试验,共335名2-6岁以轻中度特应性皮炎为主的儿童。
- 研究者每次访视采集SCORAD和IGA,家长每周两次使用PO-SCORAD、每周一次使用POEM。
主要发现
- PO-SCORAD与SCORAD强相关(r=0.874),与POEM相关(r=0.734),与IGA相关(r=0.613)。
- SCORAD与IGA类别最佳匹配(k统计量0.68)对应的SCORAD分类为:<12(清除/几乎清除)、12-25(轻度)、≥25(中度/重度)。
- 8周内PO-SCORAD曲线下面积显著大于SCORAD(p=0.0002),能更好估计访视间疾病严重度。
- 未来7天内发作的患者在发作前7天PO-SCORAD评分显著更高(p<0.0001)。
- 中度红斑是最显著的发作预测因子(p<0.0001)。
关键数值与推荐
- PO-SCORAD与SCORAD强相关(r=0.874)。
- SCORAD分类<12对应IGA清除/几乎清除,12-25对应轻度,≥25对应中度/重度(k统计量0.68)。
- 8周内PO-SCORAD曲线下面积显著大于SCORAD(p=0.0002)。
临床怎么用
- PO-SCORAD每周使用两次可能改善特应性皮炎患者的管理。
- PO-SCORAD在常规临床实践中可能比其它评分具有更大实用性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is limited data about the clinical meaningfulness of the Scoring of Atopic Dermatitis (SCORAD) and Patient-Oriented SCORAD (PO-SCORAD), particularly in children with mild-to-moderate AD. Regular use of patient-reported outcomes, may deliver more accurate information about the overall health status of AD patients than routine but sparse physician assessments. OBJECTIVE: To confirm the correlation between SCORAD, PO-SCORAD, Patient-Oriented Eczema Measure (POEM) and Investigator's Global Assessment (IGA). To evaluate the interpretability and clinical usefulness of the SCORAD and PO-SCORAD scores in children. METHODS: Data were drawn from a 12-week randomized controlled trial in 335 children, aged 2-6 years, with mainly mild-to-moderate AD. Investigators captured SCORAD and IGA at each study visit. Parents used PO-SCORAD twice-weekly, and POEM once-weekly. RESULTS: There were strong correlations between PO-SCORAD and SCORAD (r = 0.874), PO-SCORAD and POEM (0.734) and PO-SCORAD and IGA (0.613). The best fit ('k' statistic: 0.68) between SCORAD and IGA classes was noted for the following SCORAD categories: <12 (clear/almost clear); 12-25 (mild); and ≥25 (moderate/severe). PO-SCORAD area under the curve over 8 weeks was significantly greater than that of SCORAD (p = 0.0002), giving a better estimate of disease severity between visits. Patients with a flare within the next 7 days had significantly higher PO-SCORAD scores 7 days before the flare (p < 0.0001). Moderate erythema was the most significant flare predictor (p < 0.0001). CONCLUSION: PO-SCORAD is robust and reliable and appears to warrant far greater utility in routine clinical practice than other scores. PO-SCORAD, used twice-weekly, may improve the management of patients with AD.
引用
- Barbarot S, Aubert H, Stalder JF, et al. The Patient-Oriented Scoring of Atopic Dermatitis and SCORAD in young children: New data on interpretability and clinical usefulness. J Eur Acad Dermatol Venereol. 2023. PMID: 37669855. doi:10.1111/jdv.19494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。